Monash IVF Group Stock

Monash IVF Group Equity

The The Equity of Monash IVF Group (MVF.AX) as of Aug 12, 2026 is 246.28 M AUD. In the previous year, The Equity was 241.91 M AUD — a change of 1.81% (higher).

Equity

246.28 MAUD

YoY

1.81%

Last updated:

In 2026, Monash IVF Group's equity was 246.28 M AUD, a 1.81% increase from the 241.91 M AUD equity in the previous year.

Access this data via the Eulerpool API

Monash IVF Group Stock analysis

What does Monash IVF Group do? The Monash IVF Group Ltd is a company in Australia specializing in reproductive medicine. It was founded in 1970 by Professor Gab Kovacs, who is considered one of the pioneers in the field of in-vitro fertilization (IVF). The company's history began in a small laboratory in Melbourne, where the first successful IVF procedures were performed. Over time, Monash IVF grew and expanded its focus to include other reproductive treatments such as donor egg programs, sperm donation, and cryopreservation. Monash IVF Group Ltd has since become a leading provider in Australia, with 19 clinics throughout the country. The company is not only active in Australia but also operates clinics in Malaysia and Vietnam. The business model of Monash IVF Group Ltd is centered around helping couples and individuals fulfill their desire to have children. The company offers a wide range of treatments tailored to the individual needs and circumstances of each patient. Among the services offered are not only IVF, donor egg programs, and sperm donation but also other technologies such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD). Monash IVF Group Ltd sees itself as an all-rounder and therefore also offers psychological support and guidance during and after treatments. One of the company's specialties is its comprehensive research work. The Monash IVF Group has a specialized research department actively involved in researching new reproductive technologies. The company collaborates closely with universities and leading scientific institutes to gain the latest insights in this field and achieve the best possible outcomes for its patients. Monash IVF Group Ltd is divided into various divisions, each with different focuses and offerings. The main division is the Monash IVF Clinic, specializing in reproductive health and fertility. Here, all common IVF and fertility treatments are offered. Another division is Monash IVF Fertility Diagnostics, specializing in diagnostics and screening of fertility and reproductive problems. State-of-the-art diagnostic procedures for evaluating male and female fertility are used here. Monash IVF Genomics is another division offering genetic counseling, screening, and diagnostics. Here, couples can determine their genetic risk factors for fertility problems and receive support in making the best possible decisions regarding family planning. In addition to these divisions, Monash IVF Group Ltd also offers specialized services. For example, there is the Monash IVF Donor Program, specializing in the facilitation of anonymous and open donor programs. The Monash IVF DNA Matching can also assist in the search for genetic relatives by utilizing advanced DNA profiling. As a leading company in the field of fertility, Monash IVF Group Ltd offers a wide range of products and services to help couples and individuals fulfill their desire to have children. With a long history of innovation and research, as well as a variety of divisions and offerings, the company is an important provider of reproductive medicine in Australia and beyond. Monash IVF Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Monash IVF Group's Equity

Monash IVF Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Monash IVF Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Monash IVF Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Monash IVF Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Monash IVF Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Monash IVF Group stock

The Equity of Monash IVF Group is 246.28 M AUD in 2026.

The Equity of Monash IVF Group changed from 241.91 M AUD to 246.28 M AUD, representing a 1.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Monash IVF Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Monash IVF Group historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Monash IVF Group

All Key Metrics — Monash IVF Group